Xenetic Biosciences Statistics
Want to see XBIO full AI Analyst Report?
Xenetic Biosciences (XBIO) Stock Statistics & Valuation Metrics
Total Valuation
Xenetic Biosciences has a market cap or net worth of $4.22M. The enterprise value is $204.83K.
- Market Cap
- $4.22M
- Enterprise Value
- $204.83K
Share Statistics
Xenetic Biosciences has 2,343,181 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,343,181
- Owned by Insiders
- 4.27%
- Owned by Institutions
- 1.76%
Financial Efficiency
Xenetic Biosciences’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -38.33%.
- Return on Equity (ROE)
- -0.36
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -38.33%
- Return on Capital Employed (ROCE)
- -0.38
- Revenue Per Employee
- 1.49M
- Profits Per Employee
- -1.34M
- Employee Count
- 2
- Asset Turnover
- 0.36
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Xenetic Biosciences is -1.51. Xenetic Biosciences’s PEG ratio is -0.03.
- PE Ratio
- -1.51
- PS Ratio
- 1.29
- PB Ratio
- 0.68
- Price to FCF
- -1.82
- Price to Operating Cash Flow
- -1.79
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Xenetic Biosciences had revenue of 2.98M and earned -2.68M in profits. Earnings per share was -1.58.
- Revenue
- 2.98M
- Gross Profit
- 2.98M
- Operating Income
- -2.83M
- Pretax Income
- -2.68M
- Net Income
- -2.68M
- EBITDA
- -2.68M
- Earnings Per Share (EPS)
- -1.58
Cash Flow
In the last 12 months, operating cash flow was -2.31M and capital expenditures -6, giving a free cash flow of -2.31M billion.
- Operating Cash Flow
- -2.31M
- Free Cash Flow
- -2.31M
- Free Cash Flow per Share
- -1.01
Dividends & Yields
Xenetic Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -53.43%
- Earnings Yield
- -58.40%
Stock Price Statistics
- Beta
- 0.60
- 52-Week Price Change
- -32.08%
- 50-Day Moving Average
- 2.68
- 200-Day Moving Average
- 2.84
- Relative Strength Index (RSI)
- 35.95
- Average Volume (3m)
- 74.17K
Important Dates
Xenetic Biosciences upcoming earnings date is May 13, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- May 13, 2027
- Ex-Dividend Date
- ―
Financial Position
Xenetic Biosciences as a current ratio of 8.32, with Debt / Equity ratio of 0.00%
- Current Ratio
- 8.32
- Quick Ratio
- 8.32
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.94
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Xenetic Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Xenetic Biosciences EV to EBITDA ratio is 0.87, with an EV/FCF ratio of 0.93.
- EV to Sales
- -0.66
- EV to EBITDA
- 0.87
- EV to Free Cash Flow
- 0.93
- EV to Operating Cash Flow
- 0.93
Balance Sheet
Xenetic Biosciences has $6.47M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.47M billion.
- Cash & Marketable Securities
- $6.47M
- Total Debt
- $0.00
- Net Cash
- $6.47M
- Net Cash Per Share
- $2.76
- Tangible Book Value Per Share
- $2.65
Margins
Gross margin is 100.00%, with operating margin of -81.01%, and net profit margin of -75.90%.
- Gross Margin
- 100.00%
- Operating Margin
- -81.01%
- Pretax Margin
- -75.90%
- Net Profit Margin
- -75.90%
- EBITDA Margin
- -75.90%
- EBIT Margin
- -75.90%
Analyst Forecast
The average price target for Xenetic Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 33.30%
- EPS Growth Forecast
- 40.59%
Scores
- Smart Score
- ―
- AI Score
- 48
